Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

7.93

+0.57 (7.74%)

At close: Aug 7, 2026, 4:00 PM EDT

7.95

+0.02 (0.25%)

Pre-market: Aug 10, 2026, 7:45 AM EDT

Xeris Biopharma Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-17.17	0.55	-54.84	-62.26	-94.66	-122.73
Depreciation & Amortization	12.18	12.16	12.07	12.33	12.24	1.88
Stock-Based Compensation	28.12	22.37	18.36	10.72	12.16	11.38
Other Adjustments	4.14	3.91	-3.76	-1.52	2.52	2.08
Change in Receivables	-5.06	-10.64	-1.22	-8.37	-13.37	-6.24
Changes in Inventories	-16.75	-19.29	-8.78	-14.8	-7.47	-7.42
Changes in Accounts Payable	4.83	-0.07	-9.61	6.96	-4.32	5.53
Changes in Accrued Expenses	3.53	3.31	3.65	-5.86	-11.38	12.56
Changes in Other Operating Activities	12	16.32	7.14	15.77	1.39	7.43
Operating Cash Flow	56.61	28.63	-36.98	-47.02	-102.89	-95.54
Operating Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-0.94	-0.7	-0.87	-2.26	-0.52	-1.09
Purchases of Investments	-	-	-34.49	-43.74	-	-43.02
Proceeds from Sale of Investments	-	-	40.24	40	34.99	103.6
Other Investing Activities	-	-	-	-	-	38.47
Investing Cash Flow	-0.94	-0.7	4.88	-6	34.46	97.96

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Long-Term Debt Issued	-	-	50	-	146.21	-
Long-Term Debt Repaid	-	-	-	-	-43.5	-
Net Long-Term Debt Issued (Repaid)	-	-	50	-	102.72	-
Issuance of Common Stock	25.92	22.27	1.73	0.58	30.84	27.84
Repurchase of Common Stock	-19.23	-10.88	-3.73	-1.01	-0.47	-0.53
Net Common Stock Issued (Repurchased)	6.69	11.39	-2	-0.43	30.37	27.3
Other Financing Activities	-	-	-11.83	-1.19	-5.61	-0.05
Financing Cash Flow	6.69	11.39	36.17	-1.61	127.47	27.25

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	-	-	-	-	-	-0
Net Cash Flow	62.36	39.32	4.07	-54.64	59.04	29.67

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	55.67	27.93	-37.85	-49.29	-103.42	-96.62
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	16.60%	9.57%	-18.64%	-30.07%	-93.80%	-194.84%
Free Cash Flow Per Share	0.31	0.16	-0.26	-0.36	-0.76	-1.22
Levered Free Cash Flow	-2.31	12.29	-1.24	-50.12	-2	-103.84
Unlevered Free Cash Flow	51.45	36.63	-28.71	-31	-90.78	-96.27

SEC Filings: 10-K · 10-Q